Thursday, April 21, 2016

BRIEF-Ultragenyx reports positive interim data from Phase 2 study of KRN23

* Reports positive interim data from Phase 2 study of KRN23

for the treatment of tumor-induced osteomalacia

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)